Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03560440 Completed - Clinical trials for Gram-Positive Bacterial Infections

Evaluation of the Dosing Regimen of Vancomycin in Pediatric Patients

Start date: June 2014
Phase:
Study type: Observational

In this retrospective registry the investigators wish to verify whether the current dosing regime of vancomycin is leading to the appropriate pharmacokinetic targets in pediatric patients. Therefore data will be collected from all pediatric patients hospitalized in University Hospitals Leuven between January 2012 and April 2014 who were treated with vancomycine.

NCT ID: NCT03560401 Completed - Clinical trials for Degenerative Lumbar Spinal Stenosis

Is Postoperative Bracing Necessary After Spine Surgery for Degenerative Conditions

Start date: October 20, 2015
Phase: N/A
Study type: Interventional

This study was started from Oct. 2015. This study aimed to evaluate the outcome of bracing following transforaminal lumbar interbody fusion (TLIF) in patients with degenerative lumbar spine diseases.

NCT ID: NCT03559998 Completed - Clinical trials for Undergraduate Medical Students' Learning Process in Doctor-patient Relationship Training

Learning Process of Fourth Year Medical Students During a Doctor-patient Relationship Training

APTHERA
Start date: June 2, 2018
Phase:
Study type: Observational

This study aims to explore learning process for undergraduate students in this doctor-patient relationship course. This study is one of the 3 studies included in a PhD on learning process during simulation training in psychiatry. The results of this 3 studies will aim at building a formative and summative assessment tool of competences specific to this pedagogic context.

NCT ID: NCT03559933 Completed - Clinical trials for Ventilator Induced Diaphragmatic Dysfunction (VIDD)

PEPNS System Feasibility Study

Start date: July 10, 2018
Phase: N/A
Study type: Interventional

The purpose of this feasibility study is to evaluate the safety and performance of the PEPNS System in patients that need to be mechanically ventilated for at least 48 hours and up to 7 days in the Intensive Care Unit (ICU).

NCT ID: NCT03559920 Completed - Clinical trials for Patients Who Needs Sedation After Head & Neck Surgery

The Optimal Dose of Sevoflurane Via Anaconda® in Post-operative Patient Underwent Head & Neck Surgery

Start date: April 3, 2018
Phase: N/A
Study type: Interventional

Sedation in the ICUs is very common. There is no ideal sedative yet, so research has been conducted to replace propofol and midazolam, which are the most commonly used sedatives in ICUs, by inhalation anesthetics. The investigators will sedate the patients who undergo head & neck surgery with tracheostomy for several days using sevoflurane, a kind of inhalation agent, via anesthetic conserving device. The objective of this study is to confirm the end-tidal sevoflurane concentration for inducing moderate sedation (RASS -2~-3). In addition, the investigators compare the volatile sedation with the IV(intravenous) sedation to see if the volatile sedation could reduce the amount of post-operative opioid consumption. - RASS: Richmond Agitation-Sedation Scale - RASS: Richmond Agitation-Sedation Scale

NCT ID: NCT03559647 Completed - Clinical trials for Non-Small Cell Lung Cancer (NSCLC)

The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy

Start date: May 30, 2018
Phase:
Study type: Observational

Hyperion Is A Prospective, Multicenter, Non-Interventional, Two-Cohort Study Collecting Primary Data In Patients With Locally Advanced Or Metastatic NSCLC Of Squamous Or Non-Squamous Histology After Prior Chemotherapy Being Treated With Atezolizumab In Routine Clinical Practice.

NCT ID: NCT03559413 Completed - Clinical trials for Primary/Relapsed Acute Lymphoblastic Leukemia (ALL) of Childhood, Adolescents and Young Adults

Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL

Start date: June 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this clinical study is to evaluate the feasibility and safety of an individualized peptide vaccination approach in patients with acute lymphoblastic leukemia (ALL). For this purpose, tumor-specific mutations are analyzed by comparative exome sequencing of tumor and healthy reference tissue. Expression of variants is further validated by RNA sequencing. In a second step, HLA-binding (human leukocyte antigen-binding) peptides derived from mutated protein sequences are selected for vaccination. The peptides are administered as a vaccination cocktail with adjuvant GM-CSF and Imiquimod over a course of 9 months and a total of 16 vaccinations. Primary objective is the de novo induction of a specific T cell response without unacceptable toxicity and acute GvHD (graft versus host disease).

NCT ID: NCT03559296 Completed - Clinical trials for Postmastectomy Lymphedema Syndrome

Reliability of Subcutaneous Echogenicity (SEG) Grade and Subcutaneous Echo-free Space (SEFS) Grade

Start date: July 1, 2018
Phase:
Study type: Observational

The aims of this study is to determine the inter- and intra-rater reliability of SEG and SEFS grade systems for postmastectomy lymphedema.

NCT ID: NCT03558776 Completed - Clinical trials for Endogenous Conversion of Alpha Linolenic Acid

Influence of the Background Diet on Metabolism of Land-based n-3 PUFA

KoALA
Start date: March 13, 2018
Phase: N/A
Study type: Interventional

KoALA study - assessment of the influence of the background diet on the metabolism and the bioavailability of plant n-3 PUFA from linseed oil. In particular, the study design focusses on the impact of variations in the background diet as confounding factor (e.g. variations in concurrently intake of linoleic acid (n-6)). Further, the influence of a regular intake of milk fat, in particular from free-grazing ruminants, on n-3 PUFA metabolism will be investigated.

NCT ID: NCT03558074 Completed - Clinical trials for Wet Age-related Macular Degeneration

Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration

Start date: April 20, 2018
Phase: Phase 2
Study type: Interventional

This study will evaluate the therapeutic effects and safety of 800 mg ALK4290 administered daily over a 6-week dosing period in subjects with refractory wet age-related macular degeneration (wAMD).